Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pentixapharm Holding AGFRA:PTP -3.90%20 Equity-to-Asset is 0.74 as of Jun. 2026, which is 5% below its 10-year median of 0.78. GuruFocus rates FRA:PTP with a GF Score™ of 20/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Pentixapharm Holding AG ranks better than 57.77% on this metric.
Pentixapharm Holding AG (FRA:PTP) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Pentixapharm Holding AG Equity-to-Asset Related Terms
Pentixapharm Holding AG Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PTP vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Pentixapharm Holding AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pentixapharm Holding AG Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Pentixapharm Holding AG's Equity-to-Asset falls into.
Pentixapharm Holding AG Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Pentixapharm Holding AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pentixapharm Holding AG (FRA:PTP) has a Equity-to-Asset of 0.74 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Pentixapharm Holding AG and its competitors. This is near median its historical median of 0.78. Over the past decade, Pentixapharm Holding AG's Equity-to-Asset has ranged from 0.66 to 0.96. According to the industry distribution chart, Pentixapharm Holding AG ranks #598 out of 1416 companies in the Biotechnology industry, placing it in the top 42.2%.
Is Pentixapharm Holding AG's Equity-to-Asset too high?
Pentixapharm Holding AG's current Equity-to-Asset of 0.74 is near median its 10-year median of 0.78. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 0.96. The Biotechnology industry median Equity-to-Asset is 0.68. Pentixapharm Holding AG's value of 0.74 is 8.8% above this industry median. Based on the distribution chart, Pentixapharm Holding AG ranks #598 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pentixapharm Holding AG ranks #598 out of 1416 companies for Equity-to-Asset. This puts Pentixapharm Holding AG in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Pentixapharm Holding AG's value of 0.74 is 8.8% above this benchmark. Historically, Pentixapharm Holding AG's own Equity-to-Asset has ranged from 0.66 to 0.96 over the past decade. While the company's 10-year median is 0.78 vs. the industry median of 0.68, Pentixapharm Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pentixapharm Holding AG's current Equity-to-Asset of 0.74 is 8.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Pentixapharm Holding AG and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pentixapharm Holding AG's current Equity-to-Asset is 0.74, which is near median its own 10-year median of 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (FRA:PTP) has a current Equity-to-Asset of 0.74. The current Equity-to-Asset is 0.74, which is near median its 10-year median of 0.78 and 8.8% above the Biotechnology industry median of 0.68. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Pentixapharm Holding AG (FRA:PTP), the current Equity-to-Asset is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score
Get the complete analysis for FRA:PTP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PTP has been successfully added to your 
